BioNTech Investor Day Presentation Deck
Y
Protein therapeutics
BNT312: Clinical modulation of peripheral biomarkers supports its function
in a wide range of solid tumors
Fold change
●
120
100
80
60
40
20
0 T
C1D1, pre
C1D1, 2 h
C1D1, 6 h
Doses 230 mg effectively induce
proinflammatory cytokine release
IFN-Y
C1D2
C1D3
F
C1D8
Min = 25;
Max = 28
C1D15
C2D1, pre
Fold change
20
15
10
5
0
C1D1, pre
O
C1D1, 2 h
O
C1D1, 6 h
TARC
C1D2
C1D3
C1D8
o Min = 21;
Max = 24
C1D15
C2D1, pre
Higher doses
more
effectively induced IFN-y and TARC,
indicating T cell activation and DC/APC activation, respectively
(≥30 mg dose vs <30 mg dose)
% Ki67+ CD8+ T cells
●
15
10
C1D1, pre
C1D2
Doses 230 mg effectively induce
cytotoxic T-cell proliferation
CD8+ T cells
C1D3
C1D8
O
Min = 24;
Max = 27
C1D15
C2D1, pre
Data cut-off: August 27, 2021.
Partnered with Genmab; 50:50 profit/loss collaboration.
Mean fold changes of cytokine concentrations and % of CD8+ T cells ± standard error of the mean (SEM) are displayed for high- and low-dose cohorts during the first cycle.
Minimum and maximum numbers of patients with available data (n) at any given point are displayed.
APC, antigen-presenting cell; DC, dendritic cell; TARC, thymus- and activation-regulated chemokine.
Johnson M, et al. SITC Annual Meeting 2021; Oral presentation 493.
Effector memory CD8+ T cells
% Percent Ki67+ Effector
Memory CD8+ T cells
60
50
40
C1D1, pre
C1D2-0
C1D3 o
C1D8-
o Min = 24;
Max = 27
C1D15
Higher doses more effectively
Ki67
(proliferation
induced
marker) in CD8+ T cells (≥30 mg dose vs <30 mg dose)
C2D1, pre
BIONTECH
129View entire presentation